Therapeutics Platform

About Mirimus

Mirimus is a private, preclinical-stage biotech founded in 2010 with a hybrid business model combining contract research services with internal therapeutic and diagnostic platform development. The company leverages deep expertise in RNA interference (RNAi), CRISPR, and genetic engineering to build advanced preclinical models and develop novel approaches in molecular diagnostics and therapeutics. Its scientific foundation is exceptional, being co-founded and advised by world-renowned leaders in cancer biology, genetics, and genomics. While likely generating early revenue from its service arm, Mirimus's long-term value hinges on translating its platform technologies into proprietary clinical programs.

Therapeutic Areas